Dr. William Kaye, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Warren Alpert Medical School of Brown University (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,072
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: Warren Alpert Medical School of Brown University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME0047592
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jupiter Medical Center Jupiter, FL
- Good Samaritan Medical Center West PAlm Beach, FL
Medical groups
- Palm Beach Diabetes and Endocrine Specialists PA (20 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,072
- Services billed
- 35,681
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 2,279 | 937 |
| Established patient office or other outpatient visit, 30-39 minutes | 2,177 | 885 |
| Blood test, comprehensive group of blood chemicals | 1,830 | 795 |
| Blood test, lipids (cholesterol and triglycerides) | 1,394 | 689 |
| Automated urinalysis test | 1,298 | 625 |
| Creatinine level to test for kidney function or muscle injury | 1,201 | 593 |
| Urine microalbumin (protein) analysis | 1,198 | 591 |
| Glycated protein level | 1,172 | 449 |
| Blood test, thyroid stimulating hormone (tsh) | 1,158 | 681 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 1,143 | 139 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ozempic (semaglutide) Other prescribers in West PAlm Beach, FL | 892 |
| Metformin Hcl Other prescribers in West PAlm Beach, FL | 668 |
| Synthroid (levothyroxine sodium) Other prescribers in West PAlm Beach, FL | 469 |
| Mounjaro (tirzepatide) Other prescribers in West PAlm Beach, FL | 391 |
| Jardiance (empagliflozin) Other prescribers in West PAlm Beach, FL | 386 |
| Unithroid (levothyroxine sodium) Other prescribers in West PAlm Beach, FL | 370 |
| Levothyroxine Sodium Other prescribers in West PAlm Beach, FL | 320 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in West PAlm Beach, FL | 227 |
| Rosuvastatin Calcium Other prescribers in West PAlm Beach, FL | 223 |
| Atorvastatin Calcium Other prescribers in West PAlm Beach, FL | 216 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 183 payments worth $99,755 in total to this clinician.
| Lilly USA, LLC | $61,774 |
|---|---|
| Novo Nordisk Inc | $24,857 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,288 |
| Sequel Med Tech, LLC | $259 |
| Amgen Inc. | $223 |
| Dexcom, Inc. | $192 |
| Neurocrine Biosciences, Inc. | $181 |
| Bayer HealthCare Pharmaceuticals Inc. | $162 |
| Compensation for services other than consulting (speaking, faculty) | $92,961 |
|---|---|
| Travel and Lodging | $3,776 |
| Food and Beverage | $2,949 |
| Education | $68.76 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,406 |
| Lilly USA, LLC Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $5,000 |
| Novo Nordisk Inc Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $4,069 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,125 |
| Novo Nordisk Inc Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,023 |
| Novo Nordisk Inc Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,674 |
| Novo Nordisk Inc Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,674 |
| Lilly USA, LLC Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $2,500 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,568 |
| Lilly USA, LLC Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
All 76 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Novo Nordisk Inc Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,674 |
| Novo Nordisk Inc Nov 6, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Boca Raton, FL · in-kind | $552 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 31, 2025 | Education JARDIANCE · DIABETES · in-kind | $18.85 |
| Novo Nordisk Inc Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $930 |
| Lilly USA, LLC Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $494 |
| Lilly USA, LLC Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $2,500 |
| Lilly USA, LLC Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Jun 3, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC May 23, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC May 20, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Novo Nordisk Inc May 20, 2025 | Education in-kind | $32.27 |
| Lilly USA, LLC May 14, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Novo Nordisk Inc Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,023 |
| Lilly USA, LLC Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Novo Nordisk Inc Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $930 |
| Novo Nordisk Inc Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,674 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,140 |
| Novo Nordisk Inc Apr 9, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Boca Raton, FL · in-kind | $744 |
| Lilly USA, LLC Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Apr 4, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Novo Nordisk Inc Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $930 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,140 |
| Lilly USA, LLC Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $3,125 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,140 |
| Lilly USA, LLC Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Lilly USA, LLC Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Novo Nordisk Inc Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $4,069 |
| Novo Nordisk Inc Mar 20, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Pembroke Pines, FL · in-kind | $712 |
| Lilly USA, LLC Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,140 |
| Lilly USA, LLC Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,568 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,406 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $399 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $248 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $121 |
| Lilly USA, LLC Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,140 |
| Lilly USA, LLC Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,140 |
| Lilly USA, LLC Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,250 |
| Lilly USA, LLC Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $5,000 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $419 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $336 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, FL · in-kind | $131 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, FL · in-kind | $113 |
| Novo Nordisk Inc Jan 16, 2025 | Education Ozempic; Rybelsus · Diabetes · in-kind | $17.64 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $49,737 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care…
Bayer HealthCare Pharmaceuticals Inc. - A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in part…
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chron…
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.